Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer

Trial Profile

Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Feb 2008 Status changed from in progress to completed.
    • 02 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top